메뉴 건너뛰기




Volumn 13, Issue 12, 2013, Pages 1399-1408

Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where are we now?

Author keywords

IMA901; Immune therapy; Renal cell carcinoma; Tumor associated antigen; Tumor microenvironment; Tyrosine kinase inhibitor; Vaccination

Indexed keywords

AGS 003; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BMS 936559; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; EVEROLIMUS; GIRENTUXIMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMA 901; INTERFERON; INTERLEUKIN 2; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; MONOCLONAL ANTIBODY; MVA 5T4; NIVOLUMAB; PAZOPANIB; PEPTIDE VACCINE; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RENIALE; SORAFENIB; SUNITINIB; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR VACCINE; UNCLASSIFIED DRUG; VITESPEN;

EID: 84888226348     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2013.856761     Document Type: Review
Times cited : (9)

References (88)
  • 1
    • 0028247491 scopus 로고
    • Genetic alterations in sporadic renal-cell carcinoma: Molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p
    • Brauch H, Pomer S, Hieronymus T, Schadt T, Lohrke H, Komitowski D. Genetic alterations in sporadic renal-cell carcinoma: molecular analyses of tumor suppressor gene harboring chromosomal regions 3p, 5q, and 17p. World J. Urol. 12(3), 162-168 (1994).
    • (1994) World J. Urol. , vol.12 , Issue.3 , pp. 162-168
    • Brauch, H.1    Pomer, S.2    Hieronymus, T.3    Schadt, T.4    Lohrke, H.5    Komitowski, D.6
  • 2
    • 84862874665 scopus 로고    scopus 로고
    • Second-line systemic therapy for the treatment of metastatic renal cell cancer
    • Kruck S, Bedke J, Kuczyk MA, Merseburger AS. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev. Anticancer. Ther. 12(6), 777-785 (2012).
    • (2012) Expert Rev. Anticancer. Ther. , vol.12 , Issue.6 , pp. 777-785
    • Kruck, S.1    Bedke, J.2    Kuczyk, M.A.3    Merseburger, A.S.4
  • 3
    • 77955493600 scopus 로고    scopus 로고
    • EAU guidelines on renal cell carcinoma: The 2010 update
    • Ljungberg B, Cowan NC, Hanbury DC et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58(3), 398-406 (2010).
    • (2010) Eur. Urol. , vol.58 , Issue.3 , pp. 398-406
    • Ljungberg, B.1    Cowan, N.C.2    Hanbury, D.C.3
  • 4
    • 0024381610 scopus 로고
    • Spontaneous regression in non-Hodgkin's lymphoma: Clinical and pathogenetic considerations
    • Drobyski WR, Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. Am. J. Hematol. 31(2), 138-141 (1989).
    • (1989) Am. J. Hematol. , vol.31 , Issue.2 , pp. 138-141
    • Drobyski, W.R.1    Qazi, R.2
  • 5
    • 0022501385 scopus 로고
    • Regression of metastatic renal cell carcinoma: A case report and literature review
    • Kavoussi LR, Levine SR, Kadmon D, Fair WR. Regression of metastatic renal cell carcinoma: a case report and literature review. J. Urol. 135(5), 1005-1007 (1986).
    • (1986) J. Urol. , vol.135 , Issue.5 , pp. 1005-1007
    • Kavoussi, L.R.1    Levine, S.R.2    Kadmon, D.3    Fair, W.R.4
  • 6
    • 84893663818 scopus 로고    scopus 로고
    • Targeted therapy in renal cell carcinoma: Moving from molecular agents to specific immunotherapy
    • doi:10.1007/s00345-013-1033-3 (Epub ahead of print)
    • Bedke J, Gouttefangeas C, Singh-Jasuja H, Stevanovic S, Behnes CL, Stenzl A. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J. Urol. doi:10.1007/s00345-013-1033-3 (2013) (Epub ahead of print).
    • (2013) World J. Urol.
    • Bedke, J.1    Gouttefangeas, C.2    Singh-Jasuja, H.3    Stevanovic, S.4    Behnes, C.L.5    Stenzl, A.6
  • 7
    • 84877898781 scopus 로고    scopus 로고
    • Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches
    • Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin. Biol. Ther. 13(6), 911-925 (2013).
    • (2013) Expert Opin. Biol. Ther. , vol.13 , Issue.6 , pp. 911-925
    • Bockorny, B.1    Dasanu, C.A.2
  • 8
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: The next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
    • (2011) Cell , vol.144 , Issue.5 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 10
    • 0042914703 scopus 로고    scopus 로고
    • Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer
    • Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 21(16), 3127-3132 (2003).
    • (2003) J. Clin. Oncol. , vol.21 , Issue.16 , pp. 3127-3132
    • Yang, J.C.1    Sherry, R.M.2    Steinberg, S.M.3
  • 11
    • 33644784733 scopus 로고    scopus 로고
    • IL-2 administration increases CD4+ CD25 (hi) Foxp3+ regulatory T cells in cancer patients
    • Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25 (hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6), 2409-2414 (2006).
    • (2006) Blood , vol.107 , Issue.6 , pp. 2409-2414
    • Ahmadzadeh, M.1    Rosenberg, S.A.2
  • 12
    • 34247524959 scopus 로고    scopus 로고
    • Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer
    • van der Vliet HJ, Koon HB, Yue SC et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin. Cancer Res. 13(7), 2100-2108 (2007).
    • (2007) Clin. Cancer Res. , vol.13 , Issue.7 , pp. 2100-2108
    • Van Der-Vliet, H.J.1    Koon, H.B.2    Yue, S.C.3
  • 13
    • 0027399243 scopus 로고
    • Peptides naturally presented by MHC class i molecules
    • Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11, 213-244 (1993).
    • (1993) Annu. Rev. Immunol. , vol.11 , pp. 213-244
    • Rammensee, H.G.1    Falk, K.2    Rotzschke, O.3
  • 14
    • 0037108856 scopus 로고    scopus 로고
    • Integrated functional genomics approach for the design of patient-individual antitumor vaccines
    • Weinschenk T, Gouttefangeas C, Schirle M et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62(20), 5818-5827 (2002).
    • (2002) Cancer Res. , vol.62 , Issue.20 , pp. 5818-5827
    • Weinschenk, T.1    Gouttefangeas, C.2    Schirle, M.3
  • 15
    • 0026322151 scopus 로고
    • A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
    • van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
    • (1991) Science , vol.254 , Issue.5038 , pp. 1643-1647
    • Van Der-Bruggen, P.1    Traversari, C.2    Chomez, P.3
  • 16
    • 84884268998 scopus 로고    scopus 로고
    • IMA901: A peptide vaccine in renal cell carcinoma
    • Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert opin. Investig. Drugs 22(10), 1329-1336 (2013).
    • (2013) Expert Opin. Investig. Drugs , vol.22 , Issue.10 , pp. 1329-1336
    • Bedke, J.1    Stenzl, A.2
  • 17
    • 84864662070 scopus 로고    scopus 로고
    • Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
    • Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18, 1254-1261 (2012).
    • (2012) Nat Med , vol.18 , pp. 1254-1261
    • Walter, S.1    Weinschenk, T.2    Stenzl, A.3
  • 18
    • 80053343071 scopus 로고    scopus 로고
    • Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy
    • Seremet T, Brasseur F, Coulie PG. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J. 17(5), 325-330 (2011).
    • (2011) Cancer J. , vol.17 , Issue.5 , pp. 325-330
    • Seremet, T.1    Brasseur, F.2    Coulie, P.G.3
  • 19
    • 79959568681 scopus 로고    scopus 로고
    • Vaccination therapy in renal cell carcinoma: Current position and future options in metastatic and localized disease
    • Brookman-May S, Burger M, Wieland WF, Rossler W, May M, Denzinger S. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev. Vaccines 10(6), 837-852 (2011).
    • (2011) Expert Rev. Vaccines , vol.10 , Issue.6 , pp. 837-852
    • Brookman-May, S.1    Burger, M.2    Wieland, W.F.3    Rossler, W.4    May, M.5    Denzinger, S.6
  • 20
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
    • (2010) N. Engl. J. Med. , vol.363 , Issue.5 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 21
    • 34447123763 scopus 로고    scopus 로고
    • Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
    • Small EJ, Sacks N, Nemunaitis J et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13(13), 3883-3891 (2007).
    • (2007) Clin. Cancer Res. , vol.13 , Issue.13 , pp. 3883-3891
    • Small, E.J.1    Sacks, N.2    Nemunaitis, J.3
  • 22
    • 33745247366 scopus 로고    scopus 로고
    • Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
    • Wierecky J, Muller MR, Wirths S et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66(11), 5910-5918 (2006).
    • (2006) Cancer Res. , vol.66 , Issue.11 , pp. 5910-5918
    • Wierecky, J.1    Muller, M.R.2    Wirths, S.3
  • 23
    • 70350010317 scopus 로고    scopus 로고
    • Immunotherapeutic strategies in kidney cancer-when TKIs are not enough
    • Biswas S, Eisen T. Immunotherapeutic strategies in kidney cancer-when TKIs are not enough. Nat. Rev. Clin. Oncol. 6(8), 478-487 (2009).
    • (2009) Nat. Rev. Clin. Oncol. , vol.6 , Issue.8 , pp. 478-487
    • Biswas, S.1    Eisen, T.2
  • 24
    • 10744230275 scopus 로고    scopus 로고
    • Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial
    • Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409), 594-599 (2004).
    • (2004) Lancet , vol.363 , Issue.9409 , pp. 594-599
    • Jocham, D.1    Richter, A.2    Hoffmann, L.3
  • 25
    • 46749131796 scopus 로고    scopus 로고
    • Vitespen: A vaccine for renal cancer?
    • Yang JC. Vitespen: a vaccine for renal cancer? Lancet 372(9633), 92-93 (2008).
    • (2008) Lancet , vol.372 , Issue.9633 , pp. 92-93
    • Yang, J.C.1
  • 26
    • 46749085802 scopus 로고    scopus 로고
    • An adjuvant autologous therapeutic vaccine (HSPPC-96; Vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial
    • Wood C, Srivastava P, Bukowski R et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633), 145-154 (2008).
    • (2008) Lancet , vol.372 , Issue.9633 , pp. 145-154
    • Wood, C.1    Srivastava, P.2    Bukowski, R.3
  • 27
    • 79960359817 scopus 로고    scopus 로고
    • A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib
    • Amin A, Dudek A, Logan T et al. A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib. J. Clin. Oncol. (Meeting Abstracts), 28(15 Suppl.), 4514 (2010).
    • (2010) J. Clin. Oncol. (Meeting Abstracts) , vol.28 , Issue.15 SUPPL. , pp. 4514
    • Amin, A.1    Dudek, A.2    Logan, T.3
  • 28
    • 84880944039 scopus 로고    scopus 로고
    • Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)
    • Abstract 357
    • Amin A, Dudek A, Logan T et al. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC). J. Clin. Oncol. 31(Suppl. 6), Abstract 357 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , Issue.SUPPL.. 6
    • Amin, A.1    Dudek, A.2    Logan, T.3
  • 29
    • 79961093008 scopus 로고    scopus 로고
    • Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib
    • Abstract 2532
    • Figlin RA, Nicolette CA, Amin A et al. Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib. J. Clin. Oncol. 29(Suppl.), Abstract 2532 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.SUPPL..
    • Figlin, R.A.1    Nicolette, C.A.2    Amin, A.3
  • 30
    • 70350537020 scopus 로고    scopus 로고
    • Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas
    • Attig S, Hennenlotter J, Pawelec G et al. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res. 69(21), 8412-8419 (2009).
    • (2009) Cancer Res. , vol.69 , Issue.21 , pp. 8412-8419
    • Attig, S.1    Hennenlotter, J.2    Pawelec, G.3
  • 31
    • 0025360886 scopus 로고
    • Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma
    • Osband ME, Lavin PT, Babayan RK et al. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet 335(8696), 994-998 (1990).
    • (1990) Lancet , vol.335 , Issue.8696 , pp. 994-998
    • Osband, M.E.1    Lavin, P.T.2    Babayan, R.K.3
  • 32
    • 84865554296 scopus 로고    scopus 로고
    • Emerging immunotherapies for renal cell carcinoma
    • Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann. Oncol. 23(Suppl. 8), viii35-40 (2012).
    • (2012) Ann. Oncol. , vol.23 , Issue.SUPPL.. 8
    • Escudier, B.1
  • 33
    • 0032784492 scopus 로고    scopus 로고
    • Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
    • Figlin RA, Thompson JA, Bukowski RM et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J. Clin. Oncol. 17(8), 2521-2529 (1999).
    • (1999) J. Clin. Oncol. , vol.17 , Issue.8 , pp. 2521-2529
    • Figlin, R.A.1    Thompson, J.A.2    Bukowski, R.M.3
  • 34
    • 84877129770 scopus 로고    scopus 로고
    • Adoptive cellular immunotherapy in metastatic renal cell carcinoma: A systematic review and meta-analysis
    • Tang X, Liu T, Zang X et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS ONE 8(5), e62847 (2013).
    • (2013) PLoS ONE , vol.8 , Issue.5
    • Tang, X.1    Liu, T.2    Zang, X.3
  • 35
    • 22144496809 scopus 로고    scopus 로고
    • Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes
    • Engels B, Noessner E, Frankenberger B, Blankenstein T, Schendel DJ, Uckert W. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes. Hum. Gene Ther. 16(7), 799-810 (2005).
    • (2005) Hum. Gene Ther. , vol.16 , Issue.7 , pp. 799-810
    • Engels, B.1    Noessner, E.2    Frankenberger, B.3    Blankenstein, T.4    Schendel, D.J.5    Uckert, W.6
  • 36
    • 67049156789 scopus 로고    scopus 로고
    • Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer
    • Feyerabend S, Stevanovic S, Gouttefangeas C et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 69(9), 917-927 (2009).
    • (2009) Prostate , vol.69 , Issue.9 , pp. 917-927
    • Feyerabend, S.1    Stevanovic, S.2    Gouttefangeas, C.3
  • 38
    • 0029903794 scopus 로고    scopus 로고
    • Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells
    • Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int. J. Cancer 68(1), 84-92 (1996).
    • (1996) Int. J. Cancer , vol.68 , Issue.1 , pp. 84-92
    • Carsberg, C.J.1    Myers, K.A.2    Stern, P.L.3
  • 39
    • 84888237576 scopus 로고    scopus 로고
    • Identification of preand post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cancer patients treated with MVA-5T4
    • Said R, Amato RJ. Identification of preand post-treatment markers, clinical, and laboratory parameters associated with outcome in renal cancer patients treated with MVA-5T4. Front. Oncol. 3, 185 (2013).
    • (2013) Front. Oncol. , vol.3 , pp. 185
    • Said, R.1    Amato, R.J.2
  • 40
    • 78349284842 scopus 로고    scopus 로고
    • Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study
    • Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin. Cancer Res. 16(22), 5539-5547 (2010).
    • (2010) Clin. Cancer Res. , vol.16 , Issue.22 , pp. 5539-5547
    • Amato, R.J.1    Hawkins, R.E.2    Kaufman, H.L.3
  • 41
    • 84871004671 scopus 로고    scopus 로고
    • Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (Tro Vax)
    • Harrop R, Treasure P, de Belin J et al. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (Tro Vax). Cancer Immunol. Immunother. 61(12), 2283-2294 (2012).
    • (2012) Cancer Immunol. Immunother. , vol.61 , Issue.12 , pp. 2283-2294
    • Harrop, R.1    Treasure, P.2    De Belin, J.3
  • 42
    • 78149254368 scopus 로고    scopus 로고
    • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    • Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28(31), 4722-4729 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.31 , pp. 4722-4729
    • Sampson, J.H.1    Heimberger, A.B.2    Archer, G.E.3
  • 43
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
    • Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
    • (2009) Clin. Cancer Res. , vol.15 , Issue.23 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3
  • 44
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 45
    • 78651292217 scopus 로고    scopus 로고
    • Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations
    • Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res. 39(Database issue), D913-919 (2011).
    • (2011) Nucleic Acids Res. , vol.39
    • Gonzalez-Galarza, F.F.1    Christmas, S.2    Middleton, D.3    Jones, A.R.4
  • 46
    • 84871503916 scopus 로고    scopus 로고
    • Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma
    • Bedke J, Laske K, Feyerabend S et al. Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur. Urol. Suppl. 11, e76 (2012).
    • (2012) Eur. Urol. Suppl. , vol.11
    • Bedke, J.1    Laske, K.2    Feyerabend, S.3
  • 47
    • 33645697721 scopus 로고    scopus 로고
    • A phase i trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma
    • Uemura H, Fujimoto K, Tanaka M et al. A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin. Cancer Res. 12(6), 1768-1775 (2006).
    • (2006) Clin. Cancer Res. , vol.12 , Issue.6 , pp. 1768-1775
    • Uemura, H.1    Fujimoto, K.2    Tanaka, M.3
  • 48
    • 55249100794 scopus 로고    scopus 로고
    • Bevacizumab: Direct anti-VEGF therapy in renal cell carcinoma
    • Escudier B, Cosaert J, Pisa P. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Rev. Anticancer Ther. 8(10), 1545-1557 (2008).
    • (2008) Expert Rev. Anticancer Ther. , vol.8 , Issue.10 , pp. 1545-1557
    • Escudier, B.1    Cosaert, J.2    Pisa, P.3
  • 49
    • 77952300540 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
    • Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28(13), 2144-2150 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.13 , pp. 2144-2150
    • Escudier, B.1    Bellmunt, J.2    Negrier, S.3
  • 50
    • 77952318310 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
    • Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010).
    • (2010) J. Clin. Oncol. , vol.28 , Issue.13 , pp. 2137-2143
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 51
    • 84883331795 scopus 로고    scopus 로고
    • A multinational phase II trial of bevacizumab with low-dose interferonalpha2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN
    • Melichar B, Bracarda S, Matveev V et al. A multinational phase II trial of bevacizumab with low-dose interferonalpha2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann. Oncol. 24(9), 2396-2402 (2013).
    • (2013) Ann. Oncol. , vol.24 , Issue.9 , pp. 2396-2402
    • Melichar, B.1    Bracarda, S.2    Matveev, V.3
  • 52
    • 0037314709 scopus 로고    scopus 로고
    • Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy
    • Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9(2), 802-811 (2003).
    • (2003) Clin. Cancer Res. , vol.9 , Issue.2 , pp. 802-811
    • Bui, M.H.1    Seligson, D.2    Han, K.R.3
  • 53
    • 0030017852 scopus 로고    scopus 로고
    • Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors
    • Surfus JE, Hank JA, Oosterwijk E et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. Emphasis Tumor Immunol. 19(3), 184-191 (1996).
    • (1996) J. Immunother. Emphasis Tumor Immunol. , vol.19 , Issue.3 , pp. 184-191
    • Surfus, J.E.1    Hank, J.A.2    Oosterwijk, E.3
  • 54
    • 84878454886 scopus 로고    scopus 로고
    • Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma
    • Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int. J. Mol. Sci. 14(6), 11402-11423 (2013).
    • (2013) Int. J. Mol. Sci. , vol.14 , Issue.6 , pp. 11402-11423
    • Oosterwijk-Wakka, J.C.1    Boerman, O.C.2    Mulders, P.F.3    Oosterwijk, E.4
  • 55
    • 84888227525 scopus 로고    scopus 로고
    • ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-Results and implications for adjuvant clinical trials
    • Abstract 4507
    • Belldegrun AS, Chamie K, Kloepfer P et al. ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC-Results and implications for adjuvant clinical trials. J. Clin. Oncol. 31(Suppl.), Abstract 4507 (2013).
    • (2013) J. Clin. Oncol. , vol.31 , Issue.SUPPL..
    • Belldegrun, A.S.1    Chamie, K.2    Kloepfer, P.3
  • 56
    • 14944360112 scopus 로고    scopus 로고
    • Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
    • Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6(3), 280-286 (2005).
    • (2005) Nat. Immunol. , vol.6 , Issue.3 , pp. 280-286
    • Probst, H.C.1    McCoy, K.2    Okazaki, T.3    Honjo, T.4    Van Den-Broek, M.5
  • 57
    • 84877940678 scopus 로고    scopus 로고
    • Trial watch: Peptide vaccines in cancer therapy
    • Vacchelli E, Martins I, Eggermont A et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 1(9), 1557-1576 (2012).
    • (2012) Oncoimmunology , vol.1 , Issue.9 , pp. 1557-1576
    • Vacchelli, E.1    Martins, I.2    Eggermont, A.3
  • 59
    • 33847258205 scopus 로고    scopus 로고
    • Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
    • Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol. 18(2), 226-232 (2007).
    • (2007) Ann. Oncol. , vol.18 , Issue.2 , pp. 226-232
    • Parmiani, G.1    Castelli, C.2    Pilla, L.3    Santinami, M.4    Colombo, M.P.5    Rivoltini, L.6
  • 60
    • 0027538181 scopus 로고
    • Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
    • Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993).
    • (1993) Proc. Natl Acad. Sci. USA , vol.90 , Issue.8 , pp. 3539-3543
    • Dranoff, G.1    Jaffee, E.2    Lazenby, A.3
  • 61
    • 0034047619 scopus 로고    scopus 로고
    • Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand
    • Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res. 60(12), 3239-3246 (2000).
    • (2000) Cancer Res. , vol.60 , Issue.12 , pp. 3239-3246
    • Mach, N.1    Gillessen, S.2    Wilson, S.B.3    Sheehan, C.4    Mihm, M.5    Dranoff, G.6
  • 62
    • 0031570843 scopus 로고    scopus 로고
    • Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells
    • Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells. J. Immunol. 159(2), 770-776 (1997).
    • (1997) J. Immunol. , vol.159 , Issue.2 , pp. 770-776
    • Qin, Z.1    Noffz, G.2    Mohaupt, M.3    Blankenstein, T.4
  • 63
    • 0029833732 scopus 로고    scopus 로고
    • Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer
    • Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int. J. Cancer 67(3), 333-338 (1996).
    • (1996) Int. J. Cancer , vol.67 , Issue.3 , pp. 333-338
    • Young, M.R.1    Wright, M.A.2    Lozano, Y.3    Matthews, J.P.4    Benefield, J.5    Prechel, M.M.6
  • 64
    • 0031570886 scopus 로고    scopus 로고
    • Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas
    • Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J. Immunol. 159(2), 990-996 (1997).
    • (1997) J. Immunol. , vol.159 , Issue.2 , pp. 990-996
    • Young, M.R.1    Wright, M.A.2    Pandit, R.3
  • 65
    • 4344590947 scopus 로고    scopus 로고
    • High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells
    • Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64(17), 6337-6343 (2004).
    • (2004) Cancer Res. , vol.64 , Issue.17 , pp. 6337-6343
    • Serafini, P.1    Carbley, R.2    Noonan, K.A.3    Tan, G.4    Bronte, V.5    Borrello, I.6
  • 66
    • 0030944023 scopus 로고    scopus 로고
    • Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
    • Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57(8), 1537-1546 (1997).
    • (1997) Cancer Res. , vol.57 , Issue.8 , pp. 1537-1546
    • Simons, J.W.1    Jaffee, E.M.2    Weber, C.E.3
  • 67
    • 0033998594 scopus 로고    scopus 로고
    • Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor
    • Spitler LE, Grossbard ML, Ernstoff MS et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol. 18(8), 1614-1621 (2000).
    • (2000) J. Clin. Oncol. , vol.18 , Issue.8 , pp. 1614-1621
    • Spitler, L.E.1    Grossbard, M.L.2    Ernstoff, M.S.3
  • 68
    • 0033153295 scopus 로고    scopus 로고
    • GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial
    • Simmons SJ, Tjoa BA, Rogers M et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 39(4), 291-297 (1999).
    • (1999) Prostate , vol.39 , Issue.4 , pp. 291-297
    • Simmons, S.J.1    Tjoa, B.A.2    Rogers, M.3
  • 69
    • 34248194231 scopus 로고    scopus 로고
    • Tregs and rethinking cancer immunotherapy
    • Curiel TJ. Tregs and rethinking cancer immunotherapy. J. Clin. Invest. 117(5), 1167-1174 (2007).
    • (2007) J. Clin. Invest. , vol.117 , Issue.5 , pp. 1167-1174
    • Curiel, T.J.1
  • 70
    • 58149332680 scopus 로고    scopus 로고
    • Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
    • Kusmartsev S, Su Z, Heiser A et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14(24), 8270-8278 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , Issue.24 , pp. 8270-8278
    • Kusmartsev, S.1    Su, Z.2    Heiser, A.3
  • 72
    • 47949090079 scopus 로고    scopus 로고
    • The role of myeloid cells in the promotion of tumour angiogenesis
    • Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8(8), 618-631 (2008).
    • (2008) Nat. Rev. Cancer , vol.8 , Issue.8 , pp. 618-631
    • Murdoch, C.1    Muthana, M.2    Coffelt, S.B.3    Lewis, C.E.4
  • 73
    • 84880936480 scopus 로고    scopus 로고
    • Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901
    • Walter S, Weinschenk T, Reinhardt C, Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2(1), e22246 (2013).
    • (2013) Oncoimmunology , vol.2 , Issue.1
    • Walter, S.1    Weinschenk, T.2    Reinhardt, C.3    Singh-Jasuja, H.4
  • 74
    • 84881233953 scopus 로고    scopus 로고
    • Cyclophosphamide induces a type i interferon-associated sterile inflammatory response signature in cancer patients' blood cells: Implications for cancer chemoimmunotherapy
    • Moschella F, Torelli GF, Valentini M et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin. Cancer Res. 19(15), 4249-4261 (2013).
    • (2013) Clin. Cancer Res. , vol.19 , Issue.15 , pp. 4249-4261
    • Moschella, F.1    Torelli, G.F.2    Valentini, M.3
  • 75
    • 84878589185 scopus 로고    scopus 로고
    • Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma
    • Sevko A, Sade-Feldman M, Kanterman J et al. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. J. Investig. Dermatol. 133(6), 1610-1619 (2013).
    • (2013) J. Investig. Dermatol. , vol.133 , Issue.6 , pp. 1610-1619
    • Sevko, A.1    Sade-Feldman, M.2    Kanterman, J.3
  • 76
    • 58149179532 scopus 로고    scopus 로고
    • Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
    • Finke JH, Rini B, Ireland J et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin. Cancer Res. 14(20), 6674-6682 (2008).
    • (2008) Clin. Cancer Res. , vol.14 , Issue.20 , pp. 6674-6682
    • Finke, J.H.1    Rini, B.2    Ireland, J.3
  • 77
    • 63549105681 scopus 로고    scopus 로고
    • Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients
    • Ko JS, Zea AH, Rini BI et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15(6), 2148-2157 (2009).
    • (2009) Clin. Cancer Res. , vol.15 , Issue.6 , pp. 2148-2157
    • Ko, J.S.1    Zea, A.H.2    Rini, B.I.3
  • 78
    • 84878758972 scopus 로고    scopus 로고
    • Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors
    • Stehle F, Schulz K, Fahldieck C et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J. Biol. Chem. 288(23), 16334-16347 (2013).
    • (2013) J. Biol. Chem. , vol.288 , Issue.23 , pp. 16334-16347
    • Stehle, F.1    Schulz, K.2    Fahldieck, C.3
  • 79
    • 47049127786 scopus 로고    scopus 로고
    • Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
    • Hipp MM, Hilf N, Walter S et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111(12), 5610-5620 (2008).
    • (2008) Blood , vol.111 , Issue.12 , pp. 5610-5620
    • Hipp, M.M.1    Hilf, N.2    Walter, S.3
  • 80
    • 84866874594 scopus 로고    scopus 로고
    • Immunological effects of multikinase inhibitors for kidney cancer: A clue for integration with cellular therapies?
    • Porta C, Paglino C, Imarisio I, Ganini C, Pedrazzoli P. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J. Cancer. 2, 333-338 (2011).
    • (2011) J. Cancer. , vol.2 , pp. 333-338
    • Porta, C.1    Paglino, C.2    Imarisio, I.3    Ganini, C.4    Pedrazzoli, P.5
  • 81
    • 0035056017 scopus 로고    scopus 로고
    • CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy
    • Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
    • (2001) Annu. Rev. Immunol. , vol.19 , pp. 565-594
    • Chambers, C.A.1    Kuhns, M.S.2    Egen, J.G.3    Allison, J.P.4
  • 82
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
    • (2010) N. Engl. J. Med. , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 83
    • 37349072460 scopus 로고    scopus 로고
    • Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    • Yang JC, Hughes M, Kammula U et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 30(8), 825-830 (2007).
    • (2007) J. Immunother. , vol.30 , Issue.8 , pp. 825-830
    • Yang, J.C.1    Hughes, M.2    Kammula, U.3
  • 84
    • 18544380239 scopus 로고    scopus 로고
    • Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
    • Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002).
    • (2002) Nat. Med. , vol.8 , Issue.8 , pp. 793-800
    • Dong, H.1    Strome, S.E.2    Salomao, D.R.3
  • 85
    • 0038273853 scopus 로고    scopus 로고
    • Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
    • Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9(5), 562-567 (2003).
    • (2003) Nat. Med. , vol.9 , Issue.5 , pp. 562-567
    • Curiel, T.J.1    Wei, S.2    Dong, H.3
  • 86
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012).
    • (2012) N. Engl. J. Med. , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 87
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013).
    • (2013) N. Engl. J. Med. , vol.369 , Issue.2 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 88
    • 37349077911 scopus 로고    scopus 로고
    • The CIMT-monitoring panel: A two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays
    • Britten CM, Gouttefangeas C, Welters MJ et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 57(3), 289-302 (2008).
    • (2008) Cancer Immunol. Immunother. , vol.57 , Issue.3 , pp. 289-302
    • Britten, C.M.1    Gouttefangeas, C.2    Welters, M.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.